leadf
logo-loader
viewAIM ImmunoTech Inc

Hemispherx Biopharma advances expanded access program for its therapy Ampligen

Hemispherx BioPharma Inc (NYSEAmerican:HEB) CEO Tom Equels tells Proactive Investors the Florida-based immunopharma company has shipped more than 300 recently manufactured vials of Ampligen to the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) clinical site at Incline Village, Nevada.

Equels says the vials will be used in the Expanded Access Program, authorized by the FDA to treat ME/CFS patients in an effort to expand compassionate care treatment to treat the disease where there is no commercially approved therapy.

Quick facts: AIM ImmunoTech Inc

Price: 2.16 USD

NYSE:AIM
Market: NYSE
Market Cap: $85.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

AIM Immunotech forms Phase 1/2a clinical trial agreement to fight the...

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive that it has struck a clinical trial agreement with Roswell Park Comprehensive Cancer Center to support its Phase 1/2a trial of Ampligen in combination with interferon alfa-2b, in cancer patients with the coronavirus. What's...

on 07/20/2020

2 min read